Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics

Max W. Adelman; Deborah A. McFarland; Mulugeta Tsegaye; Abraham Aseffa; Russell R. Kempker; Henry M. Blumberg

doi:10.1093/ofid/ofx269

Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics

Max W. Adelman, Deborah A. McFarland, Mulugeta Tsegaye, Abraham Aseffa, Russell R. Kempker, Henry M. Blumberg

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background: The World Health Organization (WHO) recommends active tuberculosis (TB) case finding and a rapid molecular diagnostic test (Xpert MTB/RIF) to detect TB among people living with HIV (PLHIV) in high-burden settings. Information on the cost-effectiveness of these recommended strategies is crucial for their implementation. Methods: We conducted a model-based cost-effectiveness analysis comparing 2 algorithms for TB screening and diagnosis at Ethiopian HIV clinics: (1) WHO-recommended symptom screen combined with Xpert for PLHIV with a positive symptom screen and (2) current recommended practice algorithm (CRPA; based on symptom screening, smear microscopy, and clinical TB diagnosis). Our primary outcome was US$ per disability-adjusted life-year (DALY) averted. Secondary outcomes were additional true-positive diagnoses, and false-negative and false-positive diagnoses averted. Results: Compared with CRPA, combining a WHO-recommended symptom screen with Xpert was highly cost-effective (incremental cost of $5 per DALY averted). Among a cohort of 15 000 PLHIV with a TB prevalence of 6% (900 TB cases), this algorithm detected 8 more true-positive cases than CRPA, and averted 2045 false-positive and 8 false-negative diagnoses compared with CRPA. The WHO-recommended algorithm was marginally costlier ($240 000) than CRPA ($239 000). In sensitivity analysis, the symptom screen/Xpert algorithm was dominated at low Xpert sensitivity (66%). Conclusions: In this model-based analysis, combining a WHO-recommended symptom screen with Xpert for TB diagnosis among PLHIV was highly cost-effective ($5 per DALY averted) and more sensitive than CRPA in a high-burden, resource-limited setting.

Original language	English (US)
Article number	ofx269
Journal	Open Forum Infectious Diseases
Volume	5
Issue number	1
DOIs	https://doi.org/10.1093/ofid/ofx269
State	Published - Jan 1 2018

Keywords

Ethiopia
TB/HIV co-infection.
cost-Effectiveness
developing countries
modeling

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofx269

Cite this

@article{c4bd8bec200747859ef486e7f55713df,

title = "Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics",

abstract = "Background: The World Health Organization (WHO) recommends active tuberculosis (TB) case finding and a rapid molecular diagnostic test (Xpert MTB/RIF) to detect TB among people living with HIV (PLHIV) in high-burden settings. Information on the cost-effectiveness of these recommended strategies is crucial for their implementation. Methods: We conducted a model-based cost-effectiveness analysis comparing 2 algorithms for TB screening and diagnosis at Ethiopian HIV clinics: (1) WHO-recommended symptom screen combined with Xpert for PLHIV with a positive symptom screen and (2) current recommended practice algorithm (CRPA; based on symptom screening, smear microscopy, and clinical TB diagnosis). Our primary outcome was US$ per disability-adjusted life-year (DALY) averted. Secondary outcomes were additional true-positive diagnoses, and false-negative and false-positive diagnoses averted. Results: Compared with CRPA, combining a WHO-recommended symptom screen with Xpert was highly cost-effective (incremental cost of $5 per DALY averted). Among a cohort of 15 000 PLHIV with a TB prevalence of 6% (900 TB cases), this algorithm detected 8 more true-positive cases than CRPA, and averted 2045 false-positive and 8 false-negative diagnoses compared with CRPA. The WHO-recommended algorithm was marginally costlier ($240 000) than CRPA ($239 000). In sensitivity analysis, the symptom screen/Xpert algorithm was dominated at low Xpert sensitivity (66%). Conclusions: In this model-based analysis, combining a WHO-recommended symptom screen with Xpert for TB diagnosis among PLHIV was highly cost-effective ($5 per DALY averted) and more sensitive than CRPA in a high-burden, resource-limited setting.",

keywords = "Ethiopia, TB/HIV co-infection., cost-Effectiveness, developing countries, modeling",

author = "Adelman, {Max W.} and McFarland, {Deborah A.} and Mulugeta Tsegaye and Abraham Aseffa and Kempker, {Russell R.} and Blumberg, {Henry M.}",

note = "Funding Information: Financial support. This work was supported in part by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (grant numbers UL1TR000454, UL1TR002378 and TL1TR000456); Fogarty International Center at the NIH (grant number D43TW009127); the NIH National Institute of Allergy and Infectious Diseases (grant number K23AI103044); the Emory Global Health Institute; the Infectious Diseases Society of America; and the American Medical Association Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: {\textcopyright} 2018 Oxford University Press. All rights reserved.",

year = "2018",

month = jan,

day = "1",

doi = "10.1093/ofid/ofx269",

language = "English (US)",

volume = "5",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics

AU - Adelman, Max W.

AU - McFarland, Deborah A.

AU - Tsegaye, Mulugeta

AU - Aseffa, Abraham

AU - Kempker, Russell R.

AU - Blumberg, Henry M.

N1 - Funding Information: Financial support. This work was supported in part by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (grant numbers UL1TR000454, UL1TR002378 and TL1TR000456); Fogarty International Center at the NIH (grant number D43TW009127); the NIH National Institute of Allergy and Infectious Diseases (grant number K23AI103044); the Emory Global Health Institute; the Infectious Diseases Society of America; and the American Medical Association Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: © 2018 Oxford University Press. All rights reserved.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The World Health Organization (WHO) recommends active tuberculosis (TB) case finding and a rapid molecular diagnostic test (Xpert MTB/RIF) to detect TB among people living with HIV (PLHIV) in high-burden settings. Information on the cost-effectiveness of these recommended strategies is crucial for their implementation. Methods: We conducted a model-based cost-effectiveness analysis comparing 2 algorithms for TB screening and diagnosis at Ethiopian HIV clinics: (1) WHO-recommended symptom screen combined with Xpert for PLHIV with a positive symptom screen and (2) current recommended practice algorithm (CRPA; based on symptom screening, smear microscopy, and clinical TB diagnosis). Our primary outcome was US$ per disability-adjusted life-year (DALY) averted. Secondary outcomes were additional true-positive diagnoses, and false-negative and false-positive diagnoses averted. Results: Compared with CRPA, combining a WHO-recommended symptom screen with Xpert was highly cost-effective (incremental cost of $5 per DALY averted). Among a cohort of 15 000 PLHIV with a TB prevalence of 6% (900 TB cases), this algorithm detected 8 more true-positive cases than CRPA, and averted 2045 false-positive and 8 false-negative diagnoses compared with CRPA. The WHO-recommended algorithm was marginally costlier ($240 000) than CRPA ($239 000). In sensitivity analysis, the symptom screen/Xpert algorithm was dominated at low Xpert sensitivity (66%). Conclusions: In this model-based analysis, combining a WHO-recommended symptom screen with Xpert for TB diagnosis among PLHIV was highly cost-effective ($5 per DALY averted) and more sensitive than CRPA in a high-burden, resource-limited setting.

AB - Background: The World Health Organization (WHO) recommends active tuberculosis (TB) case finding and a rapid molecular diagnostic test (Xpert MTB/RIF) to detect TB among people living with HIV (PLHIV) in high-burden settings. Information on the cost-effectiveness of these recommended strategies is crucial for their implementation. Methods: We conducted a model-based cost-effectiveness analysis comparing 2 algorithms for TB screening and diagnosis at Ethiopian HIV clinics: (1) WHO-recommended symptom screen combined with Xpert for PLHIV with a positive symptom screen and (2) current recommended practice algorithm (CRPA; based on symptom screening, smear microscopy, and clinical TB diagnosis). Our primary outcome was US$ per disability-adjusted life-year (DALY) averted. Secondary outcomes were additional true-positive diagnoses, and false-negative and false-positive diagnoses averted. Results: Compared with CRPA, combining a WHO-recommended symptom screen with Xpert was highly cost-effective (incremental cost of $5 per DALY averted). Among a cohort of 15 000 PLHIV with a TB prevalence of 6% (900 TB cases), this algorithm detected 8 more true-positive cases than CRPA, and averted 2045 false-positive and 8 false-negative diagnoses compared with CRPA. The WHO-recommended algorithm was marginally costlier ($240 000) than CRPA ($239 000). In sensitivity analysis, the symptom screen/Xpert algorithm was dominated at low Xpert sensitivity (66%). Conclusions: In this model-based analysis, combining a WHO-recommended symptom screen with Xpert for TB diagnosis among PLHIV was highly cost-effective ($5 per DALY averted) and more sensitive than CRPA in a high-burden, resource-limited setting.

KW - Ethiopia

KW - TB/HIV co-infection.

KW - cost-Effectiveness

KW - developing countries

KW - modeling

UR - http://www.scopus.com/inward/record.url?scp=85051636625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051636625&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofx269

DO - 10.1093/ofid/ofx269

M3 - Article

AN - SCOPUS:85051636625

SN - 2328-8957

VL - 5

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 1

M1 - ofx269

ER -

Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this